Roche Launches AXELIOS 1 Next-Generation Sequencing Platform
Roche Launches AXELIOS 1 Sequencing Platform to Advance Genomics Research with Innovative SBX Technology Roche has announced the commercial launch of AXELIOS 1, a next-generation sequencing platform powered by its…
Merck Partners with ADAP Crisis Task Force to Expand HIV Care Access
Merck Expands Access to New HIV Treatment IDVYNSO™ Through Agreement with the ADAP Crisis Task Force Merck, known as MSD outside the United States and Canada, has announced a new…
DePuy Synthes Names Christina Zamarro as Chief Financial Officer
DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer to Support Continued Global Growth DePuy Synthes, a global leader in orthopaedic technologies and solutions, has announced the appointment of Christina…
SKYRIZI Receives FDA Approval for Pediatric Psoriatic Disease
SKYRIZI® Gains FDA Approval for Use in Children with Psoriatic Disease AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of…
Novo Nordisk to Present New Haemophilia Data at ISTH 2026
Novo Nordisk to Showcase New Haemophilia Research and Investigational Denecimig Data at ISTH 2026 Congress Novo Nordisk has announced that it will present an extensive portfolio of new scientific data…
Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume with EPI-321 in FSHD Patients
Epicrispr Biotechnologies Reports Promising Phase 1/2 Data Showing Increased Muscle Volume with EPI-321 in Patients with Facioscapulohumeral Muscular Dystrophy Epicrispr Biotechnologies, a clinical-stage biotechnology company focused on developing epigenetic therapies,…
Incyte Receives Positive CHMP Opinion for Opzelura in Adult Atopic Dermatitis
Incyte Receives Positive CHMP Opinion for Opzelura® Cream in Adults with Moderate Atopic Dermatitis Incyte has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…
CHMP Recommends EU Approval of DAYBU® (Trofinetide)
CHMP Recommends EU Approval of DAYBUE® (trofinetide) Acadia Pharmaceuticals Inc. has announced a significant regulatory milestone for its rare disease portfolio after the Committee for Medicinal Products for Human Use…
Stallergenes Greer Named Among Switzerland’s Best Managed Companies 2026
Stallergenes Greer Earns 2026 Switzerland’s Best Managed Companies Award for Excellence in Leadership, Innovation, and Sustainable Growth Stallergenes Greer, a global leader in allergy immunotherapy and allergy care, has been…
MaaT Pharma to Request Re-Examination of Negative CHMP Opinion for MaaT013
MaaT Pharma to Seek EMA Re-Examination After CHMP Issues Negative Opinion on Conditional Marketing Application for Xervyteg® in Acute Graft-versus-Host Disease Clinical-stage biotechnology company MaaT Pharma has announced that the…
First Patient Survey Reveals Broad Impact of Rare Skin Disease Beyond the Skin
FIRST Survey Highlights the Emotional, Social, and Daily Challenges Faced by People Living with Ichthyosis, Reinforcing the Need for Better Treatments and Support The Foundation for Ichthyosis & Related Skin…
MRM Health Appoints New Chairman and Independent Director as MH002 Advances
MRM Health Strengthens Board of Directors with Two Industry Veterans as Lead Microbiome Therapy Advances Toward Late-Stage Development MRM Health, a clinical-stage biotechnology company focused on developing microbiome-based therapeutics for…